Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
H-89 in Wnt-Driven Bone Metabolism
2026-11-17
The cited study links Wnt signaling to osteogenesis through Ca2+-PKA-GFAT1 control of O-GlcNAcylation, metabolic rewiring, and PDK1 stabilization. H-89 is relevant as a pharmacological probe of the PKA branch, but the study’s broader conclusions depend on complementary metabolic, biochemical, genetic, and in vivo evidence rather than on one inhibitor alone.
H-89 and the PKA–Wnt Bone Axis
2026-11-17
A critical reading of the reported evidence places H-89 as a pharmacological probe of the PKA branch linking Wnt signaling to GFAT1, O-GlcNAcylation, glycolysis, and osteogenesis. The strongest causal support comes from genetic perturbation, metabolic measurements, PDK1 modification studies, and mouse models. Biochemical potency alone does not establish cellular selectivity, pathway exclusivity, or therapeutic benefit.
H-89 and the Wnt–O-GlcNAc Bone Mechanism
2026-11-16
The study connects Wnt3a signaling to osteoblast metabolism through a Ca2+–PKA–GFAT1 axis, O-GlcNAcylation, and PDK1 stabilization. H-89 is most informative as a pharmacological probe of the proposed PKA contribution, while genetic evidence provides the stronger basis for causal claims about O-GlcNAcylation and bone formation.
H-89 in Wnt–O-GlcNAcylation Signaling
2026-11-16
H-89 provides a pharmacological lens on the PKA branch of Wnt-driven metabolic remodeling, but the strongest evidence in the cited study comes from genetic, metabolic and site-specific analyses of O-GlcNAcylation and PDK1.
H-89 in Wnt–O-GlcNAc Bone Biology
2026-11-15
A literature-focused analysis of how H-89 relates to the proposed Ca2+–PKA–GFAT1 branch of Wnt signaling, and why the strongest evidence in the study comes from genetic, metabolic, and in vivo experiments rather than pharmacological inhibition alone.
When Context Changes a Signaling Result
2026-11-14
A kinase-inhibitor result can mean different things in a purified-enzyme assay, a cultured-cell model, and an animal phenotype. The Wnt–O-GlcNAcylation study illustrates why H-89-associated evidence should be read as pathway perturbation within a defined biological context—not as proof that PKA alone explains bone formation or that H-89 has therapeutic activity.
When Context Changes What H-89 Means
2026-11-13
A context-focused analysis of H-89 in Wnt-driven osteogenesis, distinguishing PKA perturbation from the stronger genetic, metabolic and in vivo evidence for O-GlcNAcylation and PDK1.
EX 527 and the Aging Bone–Vessel Niche
2026-11-13
Liu et al. used SIRT1 activation and inhibition to examine how aging disrupts the coupling between type H vasculature and osteogenic cells. Their findings support a β-catenin-associated model in which SIRT1 influences endothelial function, osteogenic differentiation, and bone repair, while remaining preclinical and pharmacologically constrained.
H-89 and the PKA–Wnt Bone-Formation Axis
2026-11-12
A literature-focused analysis of how H-89 informs the proposed Ca2+–PKA–GFAT1 connection between Wnt signaling, O-GlcNAcylation, glycolysis, and osteoblastogenesis.
H-89 in Wnt–O-GlcNAc Bone Signaling
2026-11-12
A literature-focused analysis of how H-89 helped interrogate the PKA-linked branch of Wnt signaling, and why the study’s strongest conclusions come from convergent genetic, metabolic, molecular, and in vivo evidence.
When Context Changes a Signaling Result
2026-11-11
H-89 can interrogate the PKA-associated portion of Wnt signaling, but its meaning depends on the model, readout, assay context, and competing mechanisms. Evidence from osteoblast-lineage genetics, metabolomics, site-specific PDK1 analysis, and in vivo bone models supports a broader O-GlcNAcylation mechanism rather than an inhibitor-only conclusion.
H-89 and the PKA–O-GlcNAcylation Axis
2026-11-11
The study positions PKA as an early branch linking Wnt signaling to GFAT1, O-GlcNAcylation, glycolytic remodeling, and osteoblast formation. H-89 is best interpreted as a pharmacological probe of that branch, while genetic, metabolic, site-specific, and in vivo evidence supplies the stronger support for the overall mechanism.
What Multiplex CRISPR Reveals—and Conceals
2026-11-10
Multiplex CRISPR–Cas links targeted DNA cleavage to gene regulation, structural variation and cell-state phenotypes, but each readout carries distinct causal limits. The strongest evidence supports multiplexing as a powerful perturbational framework, while specificity, repair heterogeneity, delivery and damage-associated confounding remain central boundaries.
How PKA Connects Wnt Signaling to Bone Formation
2026-11-10
A literature-focused analysis of how H-89, a cAMP-dependent protein kinase inhibitor, fits into evidence linking Wnt signaling, O-GlcNAcylation, glycolysis, and osteogenesis.
What LNP Comparisons Can—and Cannot—Show
2026-11-09
A transformer-based analysis of lipid nanoparticles shows that efficacy is shaped by interacting components, composition, cell context and formulation-wide features. Its results support formulation ranking under reporter-assay conditions, but do not establish how a particular modified nucleotide cargo behaves or prove clinical performance.